Global Ingredient Risk Index Botanical

Rhodiola Rosea

Rhodiola rosea

Also known as: Golden root, arctic root, roseroot, SHR-5

23 მარ 2026

LOW RISK 3.0/10 How?

This ingredient is classified as unclassified risk (GIRI score: 3.0/10).

Known Safety Concerns

Stimulating effect may cause insomnia or irritability at high doses
Possible interaction with antidepressants (MAOIs, SSRIs)
May lower blood pressure and blood sugar
Avoid in bipolar disorder -- may trigger manic episodes

Contraindications

Stimulating effect may cause insomnia or irritability at high doses
Possible interaction with antidepressants (MAOIs, SSRIs)

═══════════════════════════════════════════════════════════════════════ -->

Information not yet available for this ingredient profile.

Rhodiola rosea is an adaptogenic herb used for stress, fatigue, and cognitive performance. Clinical trials support modest benefits for stress-related fatigue. It is generally well tolerated. Stimulating effects may cause insomnia or agitation in some individuals. It may interact with antidepressants via monoamine pathways.

Scientific Name: Rhodiola rosea

Information not yet available for this ingredient profile.

SETI Score 50/100

Risk Level High risk

Scientific Confidence Low

Evidence Strength Limited

Key Benefit Botanical

Key Safety Concern Stimulating effect may cause insomnia or irritability at high doses

Evidence Reviewed 10 PubMed studies

Scientific Confidence Low

Based on study quality, consistency, and recency

Executive Summary — Ingredient Assessment

SETI Score 50/100

Risk Level High risk

Evidence Strength Limited

Main Benefit Botanical

Main Safety Concern Stimulating effect may cause insomnia or irritability at high doses

Ingredient Rhodiola Rosea

Scientific name Rhodiola rosea

Scientific Evidence Overview

10 studies reviewed
0 high-quality studies (meta-analysis or RCT)
Main clinical benefit observed: Botanical
Evidence consistency: High consistency across studies (100%)

Safety Signals

Stimulating effect may cause insomnia or irritability at high doses
Possible interaction with antidepressants (MAOIs, SSRIs)
May lower blood pressure and blood sugar
Avoid in bipolar disorder -- may trigger manic episodes

Evidence Strength Limited

Final Scientific Assessment

The available scientific evidence for Rhodiola Rosea indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.

Ingredient Rhodiola Rosea

Evidence reviewed 10 peer-reviewed studies (last 10 years)

Scientific name Rhodiola rosea

50 /100

Total SETI Score

High risk

Evidence quality	10/40
Evidence consistency	20/20
Safety signals	0/20
Study recency	10/10
Evidence transparency	10/10

Evidence Summary

10 studies reviewed
0 high-quality studies (meta-analysis or systematic review)
0 studies identified benefits or no safety concern (GREEN)
10 studies reported limited or advisory safety evidence (YELLOW)

Evidence Policy

Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.

Last updated: 15 აპრ 2026, 19:53

Evidence Distribution

10 Other / unclassified

Observational / other LOW evidence YELLOW
Adaptive Laboratory Evolution for Enhanced Tyrosol Tolerance Enables High-Titer Salidroside Production in Escherichia coli. ↗

PMID 41979105 ↗

Journal ACS Synth Biol

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41979105/

Li C et al.. Adaptive Laboratory Evolution for Enhanced Tyrosol Tolerance Enables High-Titer Salidroside Production in Escherichia coli.. ACS Synth Biol. 2026. PMID:41979105.
Observational / other LOW evidence YELLOW
Salidroside ameliorates skin aging in male mice by promoting collagen regeneration via modulation of FOS and MMP9. ↗

PMID 41961336 ↗

Journal Biogerontology

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41961336/

Wang Z et al.. Salidroside ameliorates skin aging in male mice by promoting collagen regeneration via modulation of FOS and MMP9.. Biogerontology. 2026. PMID:41961336.
Observational / other LOW evidence YELLOW
Salidroside Ameliorates Polycystic Ovary Syndrome in Mice by Regulating the AKT/NF-κB/NLRP3-HAS2 Axis. ↗

PMID 41948383 ↗

Journal Food Sci Nutr

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41948383/

Li JH et al.. Salidroside Ameliorates Polycystic Ovary Syndrome in Mice by Regulating the AKT/NF-κB/NLRP3-HAS2 Axis.. Food Sci Nutr. 2026. PMID:41948383.
Observational / other LOW evidence YELLOW
A Rhodiola-derived acidic glycopeptide maintains sleep homeostasis by regulating brain lipid metabolism in Drosophila. ↗

PMID 41931999 ↗

Journal Phytomedicine

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41931999/

Xu R et al.. A Rhodiola-derived acidic glycopeptide maintains sleep homeostasis by regulating brain lipid metabolism in Drosophila.. Phytomedicine. 2026. PMID:41931999.
Observational / other LOW evidence YELLOW
Phenolic Compounds and Elemental Composition of Rhodiola rosea (Crassulaceae) from Altai Mountains. ↗

PMID 41912825 ↗

Journal Dokl Biol Sci

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41912825/

Zibareva LN et al.. Phenolic Compounds and Elemental Composition of Rhodiola rosea (Crassulaceae) from Altai Mountains.. Dokl Biol Sci. 2026. PMID:41912825.
Observational / other LOW evidence YELLOW
Rhodiola rosea, Ginkgo biloba, and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders. ↗

PMID 41909050 ↗

Journal Front Nutr

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41909050/

Li X et al.. Rhodiola rosea, Ginkgo biloba, and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders.. Front Nutr. 2026. PMID:41909050.
Observational / other LOW evidence YELLOW
Clinical evidence for the adaptogenic effects of Withania somnifera and Rhodiola rosea - A systematic review with molecular interpretation of psychometric outcomes. ↗

PMID 41906501 ↗

Journal Ann Agric Environ Med

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41906501/

Łuszczak J et al.. Clinical evidence for the adaptogenic effects of Withania somnifera and Rhodiola rosea - A systematic review with molecular interpretation of psychometric outcomes.. Ann Agric Environ Med. 2026. PMID:41906501.
Observational / other LOW evidence YELLOW
System-Level, Molecular and Cellular Mechanisms of Selected Plant Adaptogens-A Review. ↗

PMID 41901106 ↗

Journal Nutrients

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41901106/

Such S et al.. System-Level, Molecular and Cellular Mechanisms of Selected Plant Adaptogens-A Review.. Nutrients. 2026. PMID:41901106.
Observational / other LOW evidence YELLOW
Effects of Rhodiola rosea on Physical and Decision-Making Performance in Football Players: A Randomised Controlled Trial. ↗

PMID 41829897 ↗

Journal Nutrients

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41829897/

Dou Y et al.. Effects of Rhodiola rosea on Physical and Decision-Making Performance in Football Players: A Randomised Controlled Trial.. Nutrients. 2026. PMID:41829897.
Observational / other LOW evidence YELLOW
A "Qualitative-Pharmacological-Correlation-Molecular" Integrated Workflow Reveals HIF-1α-Relevant Anti-Hypoxia Metabolites in Rhodiola Species. ↗

PMID 41828434 ↗

Journal Int J Mol Sci

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41828434/

Li Y et al.. A "Qualitative-Pharmacological-Correlation-Molecular" Integrated Workflow Reveals HIF-1α-Relevant Anti-Hypoxia Metabolites in Rhodiola Species.. Int J Mol Sci. 2026. PMID:41828434.

Q × L × D × S × 10 = 3.0 / 10

The GIRI Score is the product of four independently computed evidence components, each normalised to 0–1, then scaled to 0–10. Every component is derived exclusively from peer-reviewed references and regulatory data — no editorial judgement is applied.

0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.

Method: Q = number of approved references ÷ 10 (capped at 1.0)

50%

Limited — mostly case reports or animal studies

Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.

Benefit

Risk

50%

Mixed or neutral — roughly equal benefit and risk signals

Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.

50%

One or more monitoring-level safety signals active

Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.

0Q × 5L × 5D × 5S = 3.0 / 10

Final GIRI Score for Rhodiola Rosea. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Full methodology & data sources

The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.

References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.

LOW RISK 3.0/10

Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.

LOW
0–3.0

MODERATE
3.0–5.5

HIGH
5.5–7.5

CRITICAL
7.5–10

3.0

The score pin shows exactly where this ingredient falls on the fixed risk scale.

What drove the Low classification for Rhodiola Rosea

A score of 3.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

0 approved references.

Limited — mostly case reports or animal studies (Level 4–5).

Neutral or mixed — benefit and risk signals roughly balanced.

No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.

No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).

How are the Low / Moderate / High / Critical thresholds defined?

The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:

Level	Score	Meaning
LOW	0.0 – 2.9	Sparse or predominantly beneficial evidence. No active safety alerts.
MODERATE	3.0 – 5.4	Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups.
HIGH	5.5 – 7.4	Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended.
CRITICAL	7.5 – 10	Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision.

Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.

← Back to Ingredient Database

Rhodiola Rosea

Safety Profile

Known Safety Concerns

Contraindications

Interactions

Evidence and Scientific Findings

Ingredient Overview

Biological and Chemical Classification

Mechanism of Action

Clinical Evidence of Effectiveness

Pharmacokinetics

Recommended Dosage

SETI — Scientific Evidence Transparency Index

Executive Summary — Ingredient Assessment

Evidence Summary

Evidence Policy

Evidence Distribution

Score Transparency

Risk Level Classification

What drove the Low classification for Rhodiola Rosea

ბოლო სიახლეები

500მლ პლასტმასის წყლის ბოთლები: ფარული საზოგადოებრივი ჯანმრთელობის რისკები

სკოლამდელი განათლება – მნიშვნელობა და გამოწვევები

ბავშვის უფლებები სკოლაში

პოპულარული ამბები

საუკეთესო ფილმები კულინარიის მოყვარულებისთვის

როგორ იყენებენ ახალგაზრდები ხელოვნურ ინტელექტს – სტუდენტების ხმა

კატეგორიები

ჩვენ შესახებ

გამოგვყევი სოციალურ ქსელებში